Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology... Show more
The RSI Oscillator for NTRA moved out of oversold territory on March 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 16 similar instances when the indicator left oversold territory. In of the 16 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on April 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NTRA entered a downward trend on March 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.684) is normal, around the industry mean (23.715). P/E Ratio (0.000) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (9.881) is also within normal values, averaging (41.612).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
MISL | 30.90 | 0.59 | +1.96% |
First Trust Indxx Aerspc & Defns ETF | |||
SEMI | 22.45 | 0.19 | +0.87% |
Columbia Select Technology ETF | |||
QUAL | 172.26 | 0.97 | +0.57% |
iShares MSCI USA Quality Factor ETF | |||
TLTW | 23.96 | -0.02 | -0.09% |
iShares 20+ Year Trs Bd Buywrt Stgy ETF | |||
CAOS | 87.94 | -0.10 | -0.11% |
Alpha Architect Tail Risk ETF |
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
---|---|---|---|---|
NTRA | 100% | +1.81% | ||
ISRG - NTRA | 49% Loosely correlated | +2.15% | ||
RDNT - NTRA | 44% Loosely correlated | +3.73% | ||
GH - NTRA | 44% Loosely correlated | +2.40% | ||
VCYT - NTRA | 43% Loosely correlated | +1.93% | ||
GKOS - NTRA | 43% Loosely correlated | +3.04% | ||
More |